Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice.

Labalette C, Nouët Y, Levillayer F, Colnot S, Chen J, Claude V, Huerre M, Perret C, Buendia MA, Wei Y.

PLoS One. 2010 Apr 28;5(4):e10371. doi: 10.1371/journal.pone.0010371.

2.

FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression.

Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, Marie PJ, Fromigué O.

FASEB J. 2008 Nov;22(11):3813-22. doi: 10.1096/fj.08-106302. Epub 2008 Jul 24.

3.

FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo.

Brun J, Dieudonné FX, Marty C, Müller J, Schüle R, Patiño-García A, Lecanda F, Fromigué O, Marie PJ.

PLoS One. 2013;8(1):e55034. doi: 10.1371/journal.pone.0055034. Epub 2013 Jan 28.

4.

The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis.

Nouët Y, Dahan J, Labalette C, Levillayer F, Julien B, Jouvion G, Cairo S, Vives FL, Ribeiro A, Huerre M, Colnot S, Perret C, Nhieu JT, Tordjmann T, Buendia MA, Wei Y.

J Hepatol. 2012 Nov;57(5):1029-36. doi: 10.1016/j.jhep.2012.06.035. Epub 2012 Jul 11.

PMID:
22796152
5.

The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation.

Labalette C, Nouët Y, Sobczak-Thepot J, Armengol C, Levillayer F, Gendron MC, Renard CA, Regnault B, Chen J, Buendia MA, Wei Y.

J Biol Chem. 2008 May 30;283(22):15201-8. doi: 10.1074/jbc.M800708200. Epub 2008 Mar 31.

6.

The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities.

Li M, Wang J, Ng SS, Chan CY, Chen AC, Xia HP, Yew DT, Wong BC, Chen Z, Kung HF, Lin MC.

Glia. 2008 Sep;56(12):1328-38. doi: 10.1002/glia.20701.

PMID:
18615633
7.

The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b.

Brun J, Fromigué O, Dieudonné FX, Marty C, Chen J, Dahan J, Wei Y, Marie PJ.

Bone. 2013 Mar;53(1):6-12. doi: 10.1016/j.bone.2012.11.020. Epub 2012 Nov 29.

PMID:
23201222
8.

Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis.

Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF, Wong BC.

Gastroenterology. 2007 Mar;132(3):1066-76. Epub 2006 Dec 3.

PMID:
17383428
9.

Identification of the LIM protein FHL2 as a coactivator of beta-catenin.

Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA.

J Biol Chem. 2003 Feb 14;278(7):5188-94. Epub 2002 Dec 3.

10.

The four and a half LIM-domain 2 controls early cardiac cell commitment and expansion via regulating β-catenin-dependent transcription.

Renger A, Zafiriou MP, Noack C, Pavlova E, Becker A, Sharkova K, Bergmann MW, El-Armouche A, Zimmermann WH, Zelarayán LC.

Stem Cells. 2013 May;31(5):928-40. doi: 10.1002/stem.1332.

11.

Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration.

König K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, Kahl P, Kolanus W, Knolle P, Buettner R, Heukamp LC.

J Immunol. 2010 Aug 1;185(3):1466-75. doi: 10.4049/jimmunol.0903449. Epub 2010 Jun 30.

12.

Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins.

Park J, Will C, Martin B, Gullotti L, Friedrichs N, Buettner R, Schneider H, Ludwig S, Wixler V.

FASEB J. 2008 Jul;22(7):2508-20. doi: 10.1096/fj.07-095521. Epub 2008 Mar 20.

13.

A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis.

Gaspar C, Franken P, Molenaar L, Breukel C, van der Valk M, Smits R, Fodde R.

PLoS Genet. 2009 Jul;5(7):e1000547. doi: 10.1371/journal.pgen.1000547. Epub 2009 Jul 3.

14.

Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.

Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST.

Cancer Res. 2008 May 15;68(10):3655-61. doi: 10.1158/0008-5472.CAN-07-2940.

15.

Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts.

Bai S, Zha J, Zhao H, Ross FP, Teitelbaum SL.

J Biol Chem. 2008 Nov 7;283(45):30861-7. doi: 10.1074/jbc.M802525200. Epub 2008 Sep 3.

16.

The four-and-a-half LIM domain protein 2 regulates vascular smooth muscle phenotype and vascular tone.

Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna G, Hata A.

J Biol Chem. 2009 May 8;284(19):13202-12. doi: 10.1074/jbc.M900282200. Epub 2009 Mar 5.

17.

The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways.

Labalette C, Nouët Y, Levillayer F, Armengol C, Renard CA, Soubigou G, Xia T, Buendia MA, Wei Y.

PLoS One. 2008;3(11):e3761. doi: 10.1371/journal.pone.0003761. Epub 2008 Nov 19.

18.

Four and half lim protein 2 (FHL2) stimulates osteoblast differentiation.

Lai CF, Bai S, Uthgenannt BA, Halstead LR, McLoughlin P, Schafer BW, Chu PH, Chen J, Otey CA, Cao X, Cheng SL.

J Bone Miner Res. 2006 Jan;21(1):17-28. Epub 2005 Oct 3.

19.

Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.

Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y.

Mol Cell Biol. 2004 Dec;24(24):10689-702.

20.

Fhl2 deficiency results in osteopenia due to decreased activity of osteoblasts.

Günther T, Poli C, Müller JM, Catala-Lehnen P, Schinke T, Yin N, Vomstein S, Amling M, Schüle R.

EMBO J. 2005 Sep 7;24(17):3049-56. Epub 2005 Aug 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk